A real-world interventional multi-centre study assessing the safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccination in childhood-onset systemic lupus erythematosus (cSLE) patients
Latest Information Update: 07 Apr 2021
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions; Pharmacodynamics
- 07 Apr 2021 New trial record